#1 Clinical Trials Search in Europe

Prednisone Acetate

This article discusses a clinical trial investigating the use of Prednisone Acetate tablets in combination with other drugs for treating metastatic castration-resistant prostate cancer. The study aims to evaluate the safety and effectiveness of this combination therapy in patients with advanced prostate cancer.

Table of Contents

What is Prednisone Acetate?

Prednisone Acetate is a medication that belongs to a class of drugs called corticosteroids. It is a synthetic version of hormones naturally produced by the adrenal glands[1]. Prednisone Acetate is used to treat various medical conditions due to its anti-inflammatory and immunosuppressive properties.

Medical Conditions Treated

In the context of the clinical trials discussed, Prednisone Acetate is being used in combination with other medications to treat metastatic castration-resistant prostate cancer (mCRPC)[1][2]. This is an advanced form of prostate cancer that has spread to other parts of the body and no longer responds to treatments that lower testosterone levels.

Usage in Clinical Trials

Prednisone Acetate is being used in two Phase 3 clinical trials for patients with mCRPC:

  1. A trial comparing MK-5684 with abiraterone acetate or enzalutamide in patients who have previously received hormonal therapy and chemotherapy[1].
  2. A trial comparing MK-5684 with abiraterone acetate or enzalutamide in patients whose cancer progressed after treatment with one next-generation hormonal agent (NHA)[2].

In these trials, Prednisone Acetate is used as a supportive medication, likely to help manage side effects or enhance the effectiveness of other treatments.

Dosage and Administration

According to the clinical trial information, Prednisone Acetate is administered as follows:

  • Form: Tablet
  • Route: Oral use (taken by mouth)
  • Maximum daily dose: 10 mg
  • Maximum total dose: 12,810 mg
  • Maximum treatment period: 42 months (3.5 years)[1][2]

It’s important to note that these dosages are specific to the clinical trials and may not reflect standard treatment protocols. Always follow your doctor’s instructions regarding dosage and administration.

Potential Side Effects

While specific side effects are not mentioned in the trial data, corticosteroids like Prednisone Acetate can cause various side effects, including:

  • Increased appetite and weight gain
  • Mood changes
  • Increased blood sugar levels
  • Fluid retention
  • Weakened immune system
  • Osteoporosis (with long-term use)

Your healthcare provider will monitor you for these and other potential side effects during treatment.

Precautions and Contraindications

Based on the clinical trial exclusion criteria, patients with the following conditions may not be suitable for treatment with Prednisone Acetate:

  • History of pituitary dysfunction[1][2]
  • Poorly controlled diabetes mellitus[1][2]
  • Clinically significant abnormal serum potassium or sodium levels[1][2]
  • Active infections requiring systemic therapy[1][2]
  • Certain cardiovascular conditions[1][2]

Interactions with Other Medications

The clinical trial data suggests potential interactions with:

  • Strong CYP3A4 inducers and P-glycoprotein (P-gp) inhibitors[2]
  • Cytochrome P450 (CYP450)-inducing antiepileptic drugs[1][2]
  • Certain hormonal therapies and chemotherapy drugs[1][2]

Always inform your healthcare provider about all medications, supplements, and herbal products you are taking to avoid potential interactions.

Aspect Details
Study Type Phase Ib/II clinical trial
Condition Metastatic Castration-Resistant Prostate Cancer
Intervention TQB3823 tablets + Abiraterone acetate tablets + Prednisone acetate tablets
Primary Outcomes Dose-limiting toxicity, Recommended phase II dose, Radiographic progression-free survival
Secondary Outcomes PSA reduction, Overall response rate, Overall survival, Clinical benefit rate, Duration of response
Safety Measures Adverse event rates (up to 24 months)
Treatment Cycle 28 days

FAQ

  • What is the purpose of this clinical trial? The purpose of this clinical trial is to explore the safety and effectiveness of combining TQB3823 tablets with abiraterone acetate tablets and prednisone acetate tablets in patients with metastatic castration-resistant prostate cancer.
  • What is Prednisone Acetate and how is it used in this trial? Prednisone Acetate is a type of glucocorticoid (a steroid hormone) used in this trial as part of a combination therapy with other drugs to treat advanced prostate cancer.
  • How long does the clinical trial last? The trial consists of two phases. The first phase plans to enroll 6-12 patients, while the second phase aims to enroll 40-60 patients. The total duration of the trial is not specified, but some outcomes are measured up to 24 months.
  • What are the main outcomes being measured in this trial? The main outcomes include dose-limiting toxicity, recommended phase II dose, radiographic progression-free survival, overall response rate, overall survival, and various safety measures such as adverse event rates.
  • Who can participate in this clinical trial? The trial is designed for patients with metastatic castration-resistant prostate cancer. Specific eligibility criteria are not provided in the given information, but typically, patients must meet certain health and disease-related requirements to participate.

Ongoing Clinical Trials on Prednisone Acetate

  • Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy and Chemotherapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Austria Czechia Denmark Finland France Germany +8

  • Study Comparing MK-5684 with Abiraterone Acetate or Enzalutamide for Patients with Advanced Prostate Cancer After Hormonal Therapy

    Recruiting

    1 1 1 1
    Investigated drugs:
    Czechia Estonia France Germany Greece Hungary +9

Glossary

  • Metastatic Castration-Resistant Prostate Cancer: An advanced form of prostate cancer that has spread to other parts of the body and continues to grow despite treatments that lower testosterone levels.
  • Prednisone Acetate: A type of glucocorticoid (steroid hormone) used to reduce inflammation and suppress the immune system.
  • TQB3823: An experimental drug that inhibits poly ADP-ribose polymerase (PARP), an enzyme involved in DNA repair.
  • Abiraterone Acetate: A medication that inhibits an enzyme called cytochrome P450 17 (CYP17), which is involved in testosterone production.
  • Radiographic Progression-Free Survival (rPFS): The time from the start of treatment until the cancer shows signs of growth on imaging tests or the patient dies from any cause.
  • Overall Response Rate (ORR): The percentage of patients whose cancer shrinks or disappears after treatment.
  • Overall Survival (OS): The length of time from the start of treatment that patients are still alive.
  • Adverse Event: Any unfavorable and unintended sign, symptom, or disease temporarily associated with the use of a medical treatment or procedure.
  • Dose-Limiting Toxicity (DLT): Side effects of a drug that are severe enough to prevent an increase in dose or require a decrease in dose.
  • Prostate-Specific Antigen (PSA): A protein produced by the prostate gland; elevated levels may indicate prostate cancer or other prostate conditions.

References

  1. http://clinicaltrials.eu/trial/study-comparing-mk-5684-with-abiraterone-acetate-or-enzalutamide-for-patients-with-advanced-prostate-cancer-after-hormonal-therapy-and-chemotherapy/
  2. http://clinicaltrials.eu/trial/study-comparing-mk-5684-with-abiraterone-acetate-or-enzalutamide-for-patients-with-advanced-prostate-cancer-after-hormonal-therapy/